Fate Therapeutics (FATE) Tops Q3 EPS by 2c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• CRH plc (CRH) PT Lowered to $135 at UBS, Buy Rating Maintained
• Meta bull case increasingly playing out, Mizuho says